Display options
Cite
Yuyun MF, Jutla SK, Quinn PA, et al. Aldosterone predicts major adverse cardiovascular events in patients with acute myocardial infarction. Heart Asia. 2012;4(1):102-7doi: 10.1136/heartasia-2012-010129.
Yuyun, M. F., Jutla, S. K., Quinn, P. A., & Ng, L. L. (2012). Aldosterone predicts major adverse cardiovascular events in patients with acute myocardial infarction. Heart Asia, 4(1), 102-7. https://doi.org/10.1136/heartasia-2012-010129
Yuyun, Matthew Fomonyuy, et al. "Aldosterone predicts major adverse cardiovascular events in patients with acute myocardial infarction." Heart Asia vol. 4,1 (2012): 102-7. doi: https://doi.org/10.1136/heartasia-2012-010129
Yuyun MF, Jutla SK, Quinn PA, Ng LL. Aldosterone predicts major adverse cardiovascular events in patients with acute myocardial infarction. Heart Asia. 2012 Aug 24;4(1):102-7. doi: 10.1136/heartasia-2012-010129. eCollection 2012. PMID: 27326041; PMCID: PMC4832614.
Copy Download .nbib Format: NLM
Share it on

Heart Asia. 2012 Aug 24;4(1):102-7. doi: 10.1136/heartasia-2012-010129. eCollection 2012.

Aldosterone predicts major adverse cardiovascular events in patients with acute myocardial infarction.

Heart Asia

Matthew Fomonyuy Yuyun, Sandeep K Jutla, Paulene A Quinn, Leong L Ng

Affiliations

  1. Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, UK.

PMID: 27326041 PMCID: PMC4832614 DOI: 10.1136/heartasia-2012-010129

Abstract

OBJECTIVE: Aldosterone is associated with increased mortality in chronic heart failure patients and correlates with adverse outcomes after an acute myocardial infarction (AMI) in smaller cohorts. We evaluated the prognostic significance of plasma aldosterone in a large cohort of post-AMI patients in relation to major adverse cardiovascular events (MACE).

DESIGN: A prospective cohort study.

SETTING: University Hospitals of Leicester, UK.

PATIENTS: Consecutive 955 patients admitted with AMI. Plasma aldosterone levels were measured in these patients.

MAIN OUTCOME MEASURES: During the 2 years follow-up, MACE which was a composite of all-cause mortality, myocardial reinfarction, and hospitalisation for heart failure as well as secondary endpoints (all-cause mortality and a combination of all-cause mortality and hospitalisation for heart failure), were ascertained.

RESULTS: MACE occured in N=261, 27.3%, all-cause mortality (N=114, 11.9%) and a combination of all-cause mortality and hospitalisation for heart failure (N=176, 18.4%). Patients with MACE had significantly higher median levels of aldosterone than those without (1150.1 vs 950.4 pmol/l, p=0.0118). The multivariate adjusted HR (95% CI) for log aldosterone on MACE was 1.26 (1.01 to 1.56), p=0.041; all-cause mortality 1.60 (1.13 to 2.27), p=0.008; and combination of all-cause mortality and heart failure 1.50 (1.14 to 1.97), p=0.003.

CONCLUSIONS: The prognostic significance of aldosterone for a variety of endpoints in this large cohort of post-AMI patients is not new and adds to the findings by others. The magnitude of the increase in aldosterone secretion post infarction is higher than previously believed.

Keywords: Heart Failure; Myocardial Ischaemia And Infarction (IHD)

References

  1. Hypertension. 1995 Feb;25(2):170-3 - PubMed
  2. J Biol Chem. 1998 Feb 27;273(9):4883-91 - PubMed
  3. Eur J Pharmacol. 1995 Jul 18;290(2):69-73 - PubMed
  4. Circulation. 2002 Dec 3;106(23):2913-8 - PubMed
  5. Eur Heart J. 2010 May;31(10):1237-47 - PubMed
  6. J Am Coll Cardiol. 2010 May 11;55(19):2171-80 - PubMed
  7. J Renin Angiotensin Aldosterone Syst. 2003 Sep;4(3):155-63 - PubMed
  8. J Endocrinol. 2005 Jul;186(1):1-20 - PubMed
  9. Curr Opin Nephrol Hypertens. 2004 Mar;13(2):191-6 - PubMed
  10. Eur Heart J. 2012 Jan;33(2):191-202 - PubMed
  11. N Engl J Med. 2003 Apr 3;348(14):1309-21 - PubMed
  12. Am Heart J. 2009 Apr;157(4):680-7 - PubMed
  13. J Am Coll Cardiol. 2001 Nov 1;38(5):1375-82 - PubMed
  14. Clin J Am Soc Nephrol. 2006 Sep;1(5):1039-45 - PubMed
  15. Eur J Endocrinol. 2007 Nov;157(5):545-59 - PubMed
  16. Circulation. 2007 Apr 3;115(13):1754-61 - PubMed
  17. Hypertension. 1994 Jul;24(1):30-6 - PubMed
  18. Eur J Heart Fail. 2011 Dec;13(12 ):1305-13 - PubMed
  19. Lancet. 1999 May 8;353(9164):1547-57 - PubMed
  20. Am J Hypertens. 1997 Dec;10(12 Pt 1):1326-34 - PubMed
  21. Circulation. 2011 Feb 1;123(4):e18-e209 - PubMed
  22. Circulation. 1995 Jul 15;92(2):175-82 - PubMed
  23. Circulation. 2006 Dec 12;114(24):2604-10 - PubMed
  24. N Engl J Med. 1999 Sep 2;341(10):709-17 - PubMed
  25. Eur Heart J. 2008 Oct;29(20):2489-96 - PubMed
  26. Kidney Int. 2000 Apr;57(4):1329-36 - PubMed
  27. Kidney Int. 2005 May;67(5):1680-2 - PubMed
  28. Hypertension. 2006 Apr;47(4):656-64 - PubMed
  29. Clin Sci (Lond). 2002 Oct;103(4):425-31 - PubMed
  30. Heart Fail Rev. 2005 Jan;10(1):15-22 - PubMed
  31. Am J Pathol. 2002 Nov;161(5):1773-81 - PubMed
  32. Lancet. 1997 May 17;349(9063):1436-42 - PubMed
  33. Eur J Heart Fail. 2009 Nov;11(11):1099-105 - PubMed
  34. Circ Heart Fail. 2009 Nov;2(6):608-15 - PubMed
  35. Naunyn Schmiedebergs Arch Pharmacol. 2006 Dec;374(3):153-62 - PubMed
  36. Circulation. 2003 Nov 18;108(20):2517-23 - PubMed

Publication Types